Cell Therapy for Parkinson’s Disease

Cell Transplantation

Original Articles

Isao Date¹  Takao Yasuhara¹  Masahiro Kameda¹  Tatsuya Sasaki¹  Naoki Tajiri² 

[1] Department of Neurological Surgery, Graduate School of Medicine, Okayama University, Okayama, Japan;Department of Neurological Surgery, Graduate School of Medicine, Okayama University, Okayama, Japan;Department of Psychology, Graduate School of Psychology, Kibi International University, Okayama, Japan;

关键词: cell therapy;    dopaminergic neuron;    ES cells;    iPSCs;    transplantation;   

DOI  :  10.1177/0963689717735411

 received in 2017-02-28, accepted in 2017-05-02,  发布年份 2017

来源: Sage Journals

【 摘 要 】

Cell therapy for Parkinson’s disease (PD) began in 1979 with the transplantation of fetal rat dopamine-containing neurons that improved motor abnormalities in the PD rat model with good survival of grafts and axonal outgrowth. Thirty years have passed since the 2 clinical trials using cell transplantation for PD patients were first reported. Recently, cell therapy is expected to develop as a realistic treatment option for PD patients owing to the advancement of biotechnology represented by pluripotent stem cells. Medication using levodopa, surgery including deep brain stimulation, and rehabilitation have all been established as current therapeutic strategies. Strong therapeutic effects have been demonstrated by these treatment methods, but they have been unable to stop the progression of the disease. Fortunately, cell therapy might be a key for true neurorestoration. This review article describes the historical development of cell therapy for PD, the current status of cell therapy, and the future direction of this treatment method.

【 授权许可】

CC BY-NC   
© The Author(s) 2017

【 图 表 】

Figure 1

Figure 3.